

Corporate Presentation

April 2024



Forward Looking Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.

All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company's cash runway into the first quarter of 2025, the enrollment and success of the ENLIGHTEN Phase 3 program and BEACON Phase 2 program, the timing for reporting top line data from the Company's clinical trials including ENLIGHTEN 1, whether positive results from our Phase 2 studies, including the BEACON trial of LYR-220 de-risk our pivotal program and validate the potential of our nasal implant to treat CRS, whether our product candidates maintain a steady dose of corticosteroid at the site of disease for six months with a single administration, the anticipated demand and market size for our product candidates, and the safety and efficacy of the our product candidates. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future; the Company's need for additional funding, which may not be available; the Company's ability to continue as a going concern; the Company's limited operating history; the fact that the Company has no approved products; the fact that the Company's product candidates are in various stages of development; the fact that clinical trial data is subject to change until the completion of the applicable clinical study report, or the fact that the Company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the Company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that the Company's product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the Company's potential inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the Company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the Company must scale its in-house manufacturing capabilities or rely on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials and commercial supply; the Company's reliance on third parties to conduct its preclinical studies and clinical trials; the Company's inability to succeed in establishing and maintaining collaborative relationships; the Company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the Company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the Company's growth; effects of natural disasters, terrorism and wars; the fact that the global pandemic caused by COVID-19 could adversely impact the Company's business and operations, including the Company's clinical trials; the fact that the price of the Company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on April 30, 2024 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation also includes statistical and market data that we obtained from industry, publications and research, surveys and studies conducted by third parties or us. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. The industry in which we operate is subject to a high degree of uncertainty, change and risk due to a variety of factors, which could cause results to differ materially from those expressed in the estimates made by the independent partners and by us.

Lyra's product candidates, LYR-210 and LYR-220, have not been approved by FDA. This presentation is intended for the investor community only. Nothing herein is intended to promote the Company's product candidates.



Company Overview

Clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis



- Bioabsorbable sinonasal implant designed to deliver
 6 months of continuous anti-inflammatory therapy
- Indication: Chronic rhinosinusitis (CRS)
 - ~12% of the US population¹
 - ~50% of patients fail medical therapy²
- Pivotal Phase 3 trials ongoing
- Patent protection through 2036



Chronic Rhinosinusitis (CRS): An "Unrecognized Epidemic"¹



CRS Cardinal Symptoms¹




Nasal obstruction and congestion



Facial pain and pressure



Nasal discharge



CRS in the United States Annually



CRS patients **treated**²

~4M

CRS patients failing medical management³



CRS patients currently presenting to an ENT⁴



4

Lyra's Proprietary Drug-Eluting Implant

Polymer-Drug Complex


Designed to deliver 6 months of continuous, local drug therapy with a single placement

Engineered Elastomeric Matrix

Shape memory keeps implant in place

Bioabsorbable Mesh Scaffold


Maximizes surface area for drug release while maintaining underlying tissue function





Lyra's "Family" of CRS Product Candidates

LYR-210 and LYR-220 are designed to address the full spectrum of CRS patients where ENTs select size based on patient anatomy





Lyra Pipeline

LYR-210 and LYR-220 are designed to address the full spectrum of CRS patients where ENTs select size based on patient anatomy


Candidate	CRS Patient Type	Phase 2	Phase 3
LYR-210 Long-acting Mometasone Furoate	Chronic Rhinosinusitis Patients with Standard Anatomy (Includes Surgically Naïve Patients) ¹ ENLIGHTEN 1 Trial ENLIGHTEN 2 Trial		
LYR-220 Long-acting Mometasone Furoate	Chronic Rhinosinusitis Patients with Enlarged Anatomy due to Prior Sinus Surgery ¹ BEACON Phase 2 Trial		



LYR-210 and LYR-220 Designed to be the New Standard of Care for CRS

Only product candidate designed to provide 6 months of CRS therapy with a single treatment

- FDA-approved API/steroid: Mometasone furoate
- Designed to provide continuous anti-inflammatory therapy
- Straightforward, office-based procedure with topical anesthesia
- Administered nasally via a single-use applicator
- Designed to be replaced every 6 months






LANTERN Study Design LYR-210 Phase 2 Clinical Trial in CRS Patients

- Multicenter, randomized, blinded, controlled, dose-ranging trial
- Adult CRS patients who failed previous medical management and have not undergone FESS¹
- Primary endpoint:
 - Change from baseline in 4 cardinal symptoms composite score (4CS) at Week 4^{2,3}
- Key secondary endpoints:
 - SNOT-224
 - Individual and composite cardinal symptom scores over 24 weeks


LANTERN





1) Functional endoscopic sinus surgery; 2) The study did not meet the primary endpoint at Week 4; however, the 7,500 ug dose group showed statistically significant improvements in 4CS over sham procedure control at weeks 16, 20, and 24. Due to COVID-19, study enrollment was curtailed at 67 patients (vs. 150 planned); 3) Four Cardinal Symptom Score is a composite of nasal blockage/obstruction, facial pain/pressure, nasal discharge and loss of sense of smell; 4) SinoNasal Outcome Test is a patient reported score from 0 – 110 based on symptoms; 5) NCT04041609

LANTERN Efficacy Results Rapid and Durable Improvement in SNOT-22 Score over 24 Weeks¹



Change in SNOT-22 Total Score^{2,3}


Error bars represent standard error



1) Cervin A, et al. Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. Int Forum AllergyRhinol. 2021;1-13; 2) SinoNasal Outcome Test is a patient reported score from 0 - 110 based on symptoms; 3) Data represents the least square mean. Missing data and data post use of rescue medication was imputed by LOCF method; 4) Minimum clinically important difference

LANTERN Efficacy Results Improvement Across Three Cardinal Symptoms of CRS¹

Change in Three Cardinal Symptoms of CRS at Week 24




LYR-210 (2500ug)

■LYR-210 (7500ug)

SHAM CONTROL



LANTERN Efficacy Results Robust Effect in 3 Cardinal Symptom (3CS) Score at Week 24¹



Change in Composite of 3CS Score^{2,3}

Week 24

Error bars represent standard error




 Cervin A, et al. Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. Int Forum AllergyRhinol. 2021;1-13; 2) Mean change from baseline (CFBL) in the 7-day average score in the 3CS composite score of nasal blockage/obstruction, facial pain/pressure, and nasal discharge; 3) Post-hoc analysis; data represent LSM. P<0.05 is considered statistically significant to control.


ENLIGHTEN Program Design LYR-210 Ongoing Pivotal Phase 3 Program

- Two pivotal studies of ~180 subjects each
- Adult CRS patients each, without nasal polyps or with grade 1 nasal polyps, who have failed medical management¹
- Primary endpoint
 - Change from baseline in 3CS²
 Score at Week 24 in patients without nasal polyps
- Key secondary endpoints
 - Individual cardinal symptoms
 - SNOT-223
 - CT sinus opacification





ENLIGHTEN 2⁵





1) Up to 30 patients with nasal polyps per study; study population represents 95% of CRS patients; 2) Three Cardinal Symptom Score is as a composite of nasal blockage/obstruction, facial pain/pressure, and nasal discharge; 3) SinoNasal Outcome Test is a patient reported score from 0 – 110 based on symptoms; 4) NCT05219968; 5) NCT05295459


BEACON Study Design LYR-220 Phase 2 Clinical Study

- Randomized, blinded, shamcontrolled proof of concept study to assess safety and efficacy¹
- Adult CRS patients who have had a prior bilateral FESS and failed medical management
- Primary endpoint safety
 - Product-related serious adverse events
- Key efficacy endpoints

- 3CS Score²


- SNOT-223





BEACON Efficacy Results Robust Effect in 3 Cardinal Symptoms (3CS) Score - Weeks 4 and 24¹

Change in Composite of 3CS Score^{2,3}




Error bars represent standard error



1) Data on file as of January 5, 2024; 2) Mean change from baseline (CFBL) in the 7-day average score in the 3CS composite score of nasal blockage/obstruction, facial pain/pressure, and nasal discharge; 3) Data represent least square means. Data post rescue was censored and imputed using patient's worst observed post-baseline score. P<0.05 is considered statistically significant to control.

BEACON Efficacy Results Improvement Across Three Cardinal Symptoms of CRS¹




Change in Three Cardinal Symptoms of CRS at Week 24^{2,3}

Error bars represent standard error



1) Data on file as of January 5, 2024; 2) Mean change from baseline (CFBL) in the 7-day average score in each individual CS of nasal blockage/obstruction, facial pain/pressure, and nasal discharge; 3) Data represent least square means. Data post rescue was censored and imputed using patient's worst observed post-baseline score. P<0.05 is considered statistically significant to control.

BEACON Efficacy Results Improvement in Loss of Smell¹



1) Data on file as of January 5, 2024.

Statistically

significant (0.87-point)


improvement

over control at week 24

(p=0.026)

BEACON Efficacy Results Rapid and Durable Improvement in SNOT-22 Score over 28 Weeks¹

Change in SNOT-22 Total Score^{2,3}



Error bars represent standard error



1) Data on file as of January 5, 2024; 2) SinoNasal Outcome Test is a patient reported score from 0 – 110 based on symptoms; 3) Data represent the least square means. Data post rescue was censored and imputed using patient's worst observed post-baseline score. P<0.05 is considered statistically significant to control; 4)Minimum clinically important difference.

LYRA Product Candidates, if Approved, are Expected To Align With Current ENT Practices

Office-based procedure that ENTs are accustomed to performing


Treatment option for patients who are unwilling to undergo surgery, allowing ENTs to serve more patients in their care

Expected to fit into ENT practice reimbursement models





Targeted Go-to-Market Strategy



Anticipated Milestones

LYR-210: ENLIGHTEN Phase 3 Program

- ✓ Mid-2023: Complete enrollment in ENLIGHTEN 1
- May 2024: Topline data from ENLIGHTEN 1
- Q4 2024: Extension study data from ENLIGHTEN 1
- 2H 2024: Complete enrollment in ENLIGHTEN 2

LYR-220: BEACON Phase 2 Program

• 2024: End of Phase 2 meeting



Financial Profile

- Cash, cash equivalents and short-term investments of \$87.1 million as of March 31, 2024
- 61.0 million common shares outstanding as of April 15, 2024



THERAPEUTICS